Cellebrite DI Ltd. (NASDAQ:CLBT) Short Interest Up 15.9% in November

Cellebrite DI Ltd. (NASDAQ:CLBT) was the recipient of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 1,750,000 shares, a growth of 15.9% from the October 31st total of 1,510,000 shares. Based on an average daily volume of 1,290,000 shares, the short-interest ratio is presently 1.4 days. Approximately 2.0% of the shares of the stock are sold short.

Institutional Trading of Cellebrite DI

A number of hedge funds have recently added to or reduced their stakes in CLBT. Tidal Investments LLC raised its position in shares of Cellebrite DI by 59.3% in the third quarter. Tidal Investments LLC now owns 104,478 shares of the company’s stock valued at $1,759,000 after purchasing an additional 38,887 shares during the period. Barclays PLC lifted its holdings in shares of Cellebrite DI by 29.1% in the third quarter. Barclays PLC now owns 263,657 shares of the company’s stock worth $4,439,000 after buying an additional 59,395 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in Cellebrite DI during the third quarter valued at $4,936,000. Y Intercept Hong Kong Ltd lifted its stake in Cellebrite DI by 35.5% in the third quarter. Y Intercept Hong Kong Ltd now owns 19,510 shares of the company’s stock worth $329,000 after acquiring an additional 5,113 shares during the period. Finally, XTX Topco Ltd raised its position in shares of Cellebrite DI by 66.0% in the 3rd quarter. XTX Topco Ltd now owns 56,360 shares of the company’s stock valued at $949,000 after purchasing an additional 22,416 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CLBT. Needham & Company LLC upped their price target on shares of Cellebrite DI from $17.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, November 7th. TD Cowen boosted their price objective on Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Bank of America increased their price target on Cellebrite DI from $13.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Deutsche Bank Aktiengesellschaft lifted their price target on Cellebrite DI from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Finally, Craig Hallum lifted their target price on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI currently has an average rating of “Buy” and an average price target of $20.29.

Cellebrite DI Price Performance

Shares of Cellebrite DI stock traded up $0.04 on Tuesday, hitting $20.40. The company’s stock had a trading volume of 853,764 shares, compared to its average volume of 1,190,230. The firm has a fifty day moving average price of $18.28 and a 200-day moving average price of $15.25. Cellebrite DI has a 52-week low of $7.91 and a 52-week high of $21.00.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The company had revenue of $106.90 million for the quarter, compared to the consensus estimate of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The company’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.09 EPS. On average, equities research analysts predict that Cellebrite DI will post 0.32 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.